Additionally, this study specifically focuses on designing peptide inhibitors targeted at HER2-overexpressing lung cancer, filling a significant gap in existing HER2-targeted therapies, which are predominantly effective in breast cancer. Here, ERBB2 is linked to breast carcinoma.